InnoCare reports the initial dosing of a participant in China's Phase III trial of the TYK2 inhibitor ICP-332 for treating atopic dermatitis.

Inotuzumab Ozogamicin, also known as Besponsa, is an antibody-drug conjugate (ADC) developed by Pfizer.

AC Immune Announces Favorable Preliminary Findings from Phase 2 Study of ACI-7104.056 Active Immunotherapy for Early Parkinson’s Disease.

Risperidone is a small molecule drug that acts on the 5-HT2A and D2 receptors.

Blenrep demonstrates improved overall survival in the DREAMM-7 phase III trial for relapsed/refractory multiple myeloma.

Antisense oligonucleotide (ASO) drugs represent a significant branch of the small nucleic acid therapeutic field, functioning as molecules that regulate gene expression through specific binding to mRNA.

Levicept Unveils Promising Phase II Results for LEVI-04, a New Neurotrophin-3 Inhibitor, in Treating Moderate to Severe Osteoarthritis at ACR Convergence 2024.

Suzetrigine is a small molecule drug developed by Vertex Pharmaceuticals, Inc. It is designed to target the Nav1.8 channel.

Sandoz has obtained approval from the European Commission for Afqlir® (aflibercept), enhancing its prominent biosimilar lineup.

Infliximab is a chimeric monoclonal antibody that targets tumor necrosis factor-alpha (TNF-α). Developed by Centocor.

This opinion endorses the approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab for adult patients diagnosed with mild cognitive impairment and mild dementia due to Alzheimer's disease.

The small molecule drug, TYRA-300, developed by Tyra Biosciences, Inc., targets FGFR3 and falls under the category of rare pediatric disease.